View ValuationAngelalign Technology 将来の成長Future 基準チェック /46Angelalign Technology利益と収益がそれぞれ年間26.3%と15.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に9.7% 26.7%なると予測されています。主要情報26.3%収益成長率26.66%EPS成長率Medical Equipment 収益成長13.4%収益成長率15.8%将来の株主資本利益率9.73%アナリストカバレッジGood最終更新日28 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 08Angelalign Technology Inc. Launches Iortho Release 6.2 With New CBCT Visualization, Trimline Flexibility, And Redesigned Prescription FormAngelalign Technology Inc. launched iOrtho Release 6.2 with new improvements in CBCT visualization, new trimline flexibility and a redesigned Rx form. The release puts real clinical advances directly in doctors' hands, from fuller CBCT visualization featuring new 3D diagnostic views, to multiple trimline options, to a redesigned Rx for Primary and Refinement cases, alongside a set of optimizations that sharpen the tools doctors rely on day to day. Release 6.2 reflects Angel Aligner's continued investment in giving orthodontists the tools to treat with confidence. New improvements in CBCT Visualization: IRS (Intelligent Root System) Gold provides detailed 3D visualizations of cortical and cancellous bone, maxillary sinus, and airway structures for more comprehensive case evaluation. Updated color mapping also makes it easier to distinguish tissue types at-a-glance, helping doctors evaluate anatomical structures more efficiently during case review. Variable Trimline in Rx: For the first time, three trimline options — Standard (scalloped), Full-Arch High, and High at Posterior Teeth Only — are built directly into the Rx form, giving doctors more control at the prescription stage, before setup even starts. There's flexibility after the fact too: doctors can downgrade their trimline selection directly in iOrtho at approval, and upgrade from Posterior Only to Full-Arch on their own. Redesigned Prescription Form for Primary and Refinement Cases: For both Primary and Refinement cases, the prescription form is being redesigned for all users to give doctors more clinical control right at the point of prescription. Building on existing Rx capabilities, the updated form expands what doctors can specify at the prescription stage, giving them more clinical control before setup even begins. Refreshed Treatment Plan Interface: The 3D user interface has been redesigned to make planning faster and more intuitive. The 3D modification tools (Tooth, Features, Arch, Occlusal Plane) now sit in the top-right of the 3D view, so doctors can access and switch between them more easily. This helps doctors evaluate treatment options more efficiently and with greater confidence. Additional Improvements From Doctor Feedback: Beyond the major features, Release 6.2 includes several smaller improvements that came directly from doctor feedback. Each update addresses a specific request raised by orthodontists using the platform. iOrtho Release 6.2 went live July 1.New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (257% cash payout ratio). Share price has been volatile over the past 3 months (8.5% average weekly change). Significant insider selling over the past 3 months (€18m sold).Declared Dividend • May 20Final dividend of HK$5.47 announcedShareholders will receive a dividend of HK$5.47. Ex-date: 21st May 2026 Payment date: 8th June 2026 Dividend yield will be 63%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but not covered by cash flows (257% cash payout ratio). The dividend has increased by an average of 106% per year over the past 3 years. However, payments have been volatile during that time. EPS is expected to grow by 105% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 14Angelalign Technology Inc. Applauds European Court Rejection of Patent Infringement ClaimAngelalign Technology Inc. said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded.お知らせ • Mar 29Angelalign Technology Inc. Proposes Special Dividend for the Financial Year End December 31, 2025, Payable on June 8, 2026Angelalign Technology Inc. proposed special dividend of HKD 4.99 per share for the financial year end 31 December 2025. Date of shareholders' approval 19 May 2026, Ex-dividend date 21 May 2026, Record date 28 May 2026 and Payment date 08 June 2026.お知らせ • Mar 28+ 1 more updateAngelalign Technology Inc. announces Annual dividend, payable on June 08, 2026Angelalign Technology Inc. announced Annual dividend of HKD 0.4800 per share payable on June 08, 2026, ex-date on May 21, 2026 and record date on May 22, 2026.お知らせ • Feb 25Angelalign Technology Inc. to Report Fiscal Year 2025 Results on Mar 27, 2026Angelalign Technology Inc. announced that they will report fiscal year 2025 results on Mar 27, 2026お知らせ • Feb 13Align Technology Inc. Announces Preliminary European Court Ruling on Certain Software Features Will Have Minimal Impact on UsersAngelalign Technology Inc. said a ruling by the Unified Patent Court of Dusseldorf, Germany that it preliminarily cease its use of certain software functions that automatically update treatment plans would have minimal impact on the orthodontists and patients who use its clear aligner products. The ruling applies to certain European countries and excludes Spain, Switzerland, United Kingdom and Ireland. Angel will launch iPlan for applicable European users, which is an upgrade feature that has the same reliability and more flexibility for users. Angel denied that the Live Now feature in its iOrtho treatment planning software infringes any valid patents of Align Technology Inc. (ALGN). Angel has already filed an opposition against the patent with the European Patent Office (EPO), asserting that the claimed invention is neither novel nor inventive over the prior art, and is seeking its permanent invalidation. Angel is confident it will overcome the first- instance, non-final and preliminary injunction issued by the Dusseldorf court. For many years, Angel has focused on developing innovative solutions in the clear-aligner segment. Among its cutting-edge products are the award-winning angelButton, the angelHook, the A6 mandibular advancement system (now celebrating its ten-year anniversary), the angel KiD system, and the Intelligent Root System. The company is committed to bringing fair and healthy competition to the marketplace to benefit doctors and their patients.お知らせ • Sep 25Angelalign Technologies Remains Confident in Light of Its Competitor's New Complaint and Diversion TacticAngelalign Technology Inc. remained confident in its position in light of the fact that industry behemoth Align Technology Inc. (ALGN) has filed another meritless case against Angel, this time with the U.S. International Trade Commission. This is the latest in a barrage of lawsuits launched by Align. Angel promises an effective defense and is confident that it will prevail. The company has innovated and operated for over 20 years with a strong reputation and track record of respecting intellectual property. Angel serves doctors and patients in 60 countries and regularly receives industry-leading satisfaction ratings. Angel has proudly led the clear-aligner field in innovation for many years while also recognizing Align's founding role in creating the industry years ago. Some examples of Angel's cutting-edge products are: The angelButton™ and the angelHook™, which allow orthodontists to manage forces effectively when using elastics. The A6 mandibular advancement system, which implements the twin-block orthodontic concept for doctors to move the mandible. AngelKid, a leading system to treat mixed dentition for young patients. Intelligent Root System, which allows orthodontists to use 3D imaging for treatment planning.お知らせ • Aug 19Align Technology Initiates Patent Infringement Ligitation Against Angelalign TechnologyAlign Technology Inc. announced the filing of patent infringement lawsuits against Angelalign Technology Inc. (Angel). The lawsuits allege that Angel’s products and associated software infringe Align patents, which encompass innovations such as multilayer aligner materials, cutting-edge treatment planning, and advanced aligner features. These legal actions have been initiated in the United States, Europe and China, jurisdictions where Align has made significant investments in innovation, aligner fabrication and treatment planning. Align seeks both injunctive relief and monetary damages through these intellectual property enforcement efforts.お知らせ • Aug 09Angelalign Technology Inc. to Report First Half, 2025 Results on Aug 25, 2025Angelalign Technology Inc. announced that they will report first half, 2025 results on Aug 25, 2025お知らせ • Mar 20Angelalign Technology Inc. Proposes Special Final Dividend for the Year Ended 31 December 2024, Payable on 20 June 2025Angelalign Technology Inc. proposed special final dividend of HKD 0.38 per share for the year ended 31 December 2024. Date of shareholders' approval is 23 May 2025. Ex-dividend date is 27 May 2025. Record date is 2 June 2025. Payment date is 20 June 2025.お知らせ • Mar 05Angelalign Technology Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025Angelalign Technology Inc. announced that they will report fiscal year 2024 results on Mar 20, 2025業績と収益の成長予測DB:77D - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028644636097612/31/20275454767851012/31/20264553175831012/31/2025370285079N/A9/30/2025340263666N/A6/30/2025309242253N/A3/31/202528918535N/A12/31/202426912-1117N/A9/30/20242589-917N/A6/30/20242466-617N/A3/31/20242287019N/A12/31/20232108722N/A9/30/202319516-313N/A6/30/202318124-133N/A3/31/202318828-312N/A12/31/202218431721N/A9/30/2022179341431N/A6/30/2022190392245N/A3/31/2022201433158N/A12/31/2021200453870N/A9/30/2021182374772N/A6/30/2021167295674N/A3/31/2021145265668N/A12/31/2020125235663N/A12/31/201993105258N/A12/31/2018719N/A21N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 77Dの予測収益成長率 (年間26.3% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: 77Dの収益 ( 26.3% ) はGerman市場 ( 16.1% ) よりも速いペースで成長すると予測されています。高成長収益: 77Dの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 77Dの収益 ( 15.8% ) German市場 ( 6.6% ) よりも速いペースで成長すると予測されています。高い収益成長: 77Dの収益 ( 15.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 77Dの 自己資本利益率 は、3年後には低くなると予測されています ( 9.7 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/20 10:35終値2026/07/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Angelalign Technology Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Bo LiBofA Global ResearchYanyin ZhuChina International Capital Corporation LimitedMujun ShenCitic Securities Co., Ltd.8 その他のアナリストを表示
お知らせ • Jul 08Angelalign Technology Inc. Launches Iortho Release 6.2 With New CBCT Visualization, Trimline Flexibility, And Redesigned Prescription FormAngelalign Technology Inc. launched iOrtho Release 6.2 with new improvements in CBCT visualization, new trimline flexibility and a redesigned Rx form. The release puts real clinical advances directly in doctors' hands, from fuller CBCT visualization featuring new 3D diagnostic views, to multiple trimline options, to a redesigned Rx for Primary and Refinement cases, alongside a set of optimizations that sharpen the tools doctors rely on day to day. Release 6.2 reflects Angel Aligner's continued investment in giving orthodontists the tools to treat with confidence. New improvements in CBCT Visualization: IRS (Intelligent Root System) Gold provides detailed 3D visualizations of cortical and cancellous bone, maxillary sinus, and airway structures for more comprehensive case evaluation. Updated color mapping also makes it easier to distinguish tissue types at-a-glance, helping doctors evaluate anatomical structures more efficiently during case review. Variable Trimline in Rx: For the first time, three trimline options — Standard (scalloped), Full-Arch High, and High at Posterior Teeth Only — are built directly into the Rx form, giving doctors more control at the prescription stage, before setup even starts. There's flexibility after the fact too: doctors can downgrade their trimline selection directly in iOrtho at approval, and upgrade from Posterior Only to Full-Arch on their own. Redesigned Prescription Form for Primary and Refinement Cases: For both Primary and Refinement cases, the prescription form is being redesigned for all users to give doctors more clinical control right at the point of prescription. Building on existing Rx capabilities, the updated form expands what doctors can specify at the prescription stage, giving them more clinical control before setup even begins. Refreshed Treatment Plan Interface: The 3D user interface has been redesigned to make planning faster and more intuitive. The 3D modification tools (Tooth, Features, Arch, Occlusal Plane) now sit in the top-right of the 3D view, so doctors can access and switch between them more easily. This helps doctors evaluate treatment options more efficiently and with greater confidence. Additional Improvements From Doctor Feedback: Beyond the major features, Release 6.2 includes several smaller improvements that came directly from doctor feedback. Each update addresses a specific request raised by orthodontists using the platform. iOrtho Release 6.2 went live July 1.
New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (257% cash payout ratio). Share price has been volatile over the past 3 months (8.5% average weekly change). Significant insider selling over the past 3 months (€18m sold).
Declared Dividend • May 20Final dividend of HK$5.47 announcedShareholders will receive a dividend of HK$5.47. Ex-date: 21st May 2026 Payment date: 8th June 2026 Dividend yield will be 63%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but not covered by cash flows (257% cash payout ratio). The dividend has increased by an average of 106% per year over the past 3 years. However, payments have been volatile during that time. EPS is expected to grow by 105% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 14Angelalign Technology Inc. Applauds European Court Rejection of Patent Infringement ClaimAngelalign Technology Inc. said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded.
お知らせ • Mar 29Angelalign Technology Inc. Proposes Special Dividend for the Financial Year End December 31, 2025, Payable on June 8, 2026Angelalign Technology Inc. proposed special dividend of HKD 4.99 per share for the financial year end 31 December 2025. Date of shareholders' approval 19 May 2026, Ex-dividend date 21 May 2026, Record date 28 May 2026 and Payment date 08 June 2026.
お知らせ • Mar 28+ 1 more updateAngelalign Technology Inc. announces Annual dividend, payable on June 08, 2026Angelalign Technology Inc. announced Annual dividend of HKD 0.4800 per share payable on June 08, 2026, ex-date on May 21, 2026 and record date on May 22, 2026.
お知らせ • Feb 25Angelalign Technology Inc. to Report Fiscal Year 2025 Results on Mar 27, 2026Angelalign Technology Inc. announced that they will report fiscal year 2025 results on Mar 27, 2026
お知らせ • Feb 13Align Technology Inc. Announces Preliminary European Court Ruling on Certain Software Features Will Have Minimal Impact on UsersAngelalign Technology Inc. said a ruling by the Unified Patent Court of Dusseldorf, Germany that it preliminarily cease its use of certain software functions that automatically update treatment plans would have minimal impact on the orthodontists and patients who use its clear aligner products. The ruling applies to certain European countries and excludes Spain, Switzerland, United Kingdom and Ireland. Angel will launch iPlan for applicable European users, which is an upgrade feature that has the same reliability and more flexibility for users. Angel denied that the Live Now feature in its iOrtho treatment planning software infringes any valid patents of Align Technology Inc. (ALGN). Angel has already filed an opposition against the patent with the European Patent Office (EPO), asserting that the claimed invention is neither novel nor inventive over the prior art, and is seeking its permanent invalidation. Angel is confident it will overcome the first- instance, non-final and preliminary injunction issued by the Dusseldorf court. For many years, Angel has focused on developing innovative solutions in the clear-aligner segment. Among its cutting-edge products are the award-winning angelButton, the angelHook, the A6 mandibular advancement system (now celebrating its ten-year anniversary), the angel KiD system, and the Intelligent Root System. The company is committed to bringing fair and healthy competition to the marketplace to benefit doctors and their patients.
お知らせ • Sep 25Angelalign Technologies Remains Confident in Light of Its Competitor's New Complaint and Diversion TacticAngelalign Technology Inc. remained confident in its position in light of the fact that industry behemoth Align Technology Inc. (ALGN) has filed another meritless case against Angel, this time with the U.S. International Trade Commission. This is the latest in a barrage of lawsuits launched by Align. Angel promises an effective defense and is confident that it will prevail. The company has innovated and operated for over 20 years with a strong reputation and track record of respecting intellectual property. Angel serves doctors and patients in 60 countries and regularly receives industry-leading satisfaction ratings. Angel has proudly led the clear-aligner field in innovation for many years while also recognizing Align's founding role in creating the industry years ago. Some examples of Angel's cutting-edge products are: The angelButton™ and the angelHook™, which allow orthodontists to manage forces effectively when using elastics. The A6 mandibular advancement system, which implements the twin-block orthodontic concept for doctors to move the mandible. AngelKid, a leading system to treat mixed dentition for young patients. Intelligent Root System, which allows orthodontists to use 3D imaging for treatment planning.
お知らせ • Aug 19Align Technology Initiates Patent Infringement Ligitation Against Angelalign TechnologyAlign Technology Inc. announced the filing of patent infringement lawsuits against Angelalign Technology Inc. (Angel). The lawsuits allege that Angel’s products and associated software infringe Align patents, which encompass innovations such as multilayer aligner materials, cutting-edge treatment planning, and advanced aligner features. These legal actions have been initiated in the United States, Europe and China, jurisdictions where Align has made significant investments in innovation, aligner fabrication and treatment planning. Align seeks both injunctive relief and monetary damages through these intellectual property enforcement efforts.
お知らせ • Aug 09Angelalign Technology Inc. to Report First Half, 2025 Results on Aug 25, 2025Angelalign Technology Inc. announced that they will report first half, 2025 results on Aug 25, 2025
お知らせ • Mar 20Angelalign Technology Inc. Proposes Special Final Dividend for the Year Ended 31 December 2024, Payable on 20 June 2025Angelalign Technology Inc. proposed special final dividend of HKD 0.38 per share for the year ended 31 December 2024. Date of shareholders' approval is 23 May 2025. Ex-dividend date is 27 May 2025. Record date is 2 June 2025. Payment date is 20 June 2025.
お知らせ • Mar 05Angelalign Technology Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025Angelalign Technology Inc. announced that they will report fiscal year 2024 results on Mar 20, 2025